- Report
- January 2022
- 60 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- January 2022
- 60 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- September 2024
- 80 Pages
Japan
From €3185EUR$3,500USD£2,731GBP
- Report
- April 2023
- 116 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2022
Global
From €719EUR$790USD£616GBP
- Report
- July 2023
- 321 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2021
- 24 Pages
Global
€1200EUR$1,318USD£1,028GBP
- Report
- October 2024
- 92 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- August 2024
- 108 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- February 2024
- 101 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2022
- 307 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- November 2021
- 620 Pages
Global
From €3640EUR$4,000USD£3,121GBP
The Virus Drug market is a subset of the Infectious Diseases Drugs market, which focuses on the development and sale of drugs to treat viral infections. These drugs are designed to target specific viruses, such as HIV, hepatitis, and influenza, and can be used to treat both acute and chronic infections. They can also be used to prevent the spread of viruses, such as through vaccinations.
The Virus Drug market is highly competitive, with many companies vying for market share. Companies in the market include Gilead Sciences, Merck & Co., Pfizer, GlaxoSmithKline, Johnson & Johnson, Bristol-Myers Squibb, and Novartis. These companies are engaged in research and development of new drugs, as well as the marketing and sale of existing drugs. Show Less Read more
